Chief Scientific Officer at Ardelyx
Jeff has served as our Chief Scientific Officer since 2020. Prior to serving as our CSO, Jeff served as our senior vice president, technical operations since 2015. Before that, Jeff had served as our vice president, chemistry (since January 2011) and vice president, medicinal chemistry (since June 2008). Jeff has spent his career in the discovery and development of new chemical entities for the treatment of unmet medical needs. His discovery experience spans target ID to candidate selection, and his development chemistry expertise spans IND-enabling studies to pivotal clinical trials. Jeff has held positions of increasing responsibility at Affymax, Vicuron and Sunesis, where he was most recently the senior director of development chemistry. Jeff graduated Magna cum Laude with a B.S. in chemistry from Gonzaga University. He received his Ph.D. in bioorganic chemistry from U.C. Berkeley where he started the catalytic antibody program in the laboratory of Professor Peter Schultz. He is a Damon-Runyon Fellow and an author and inventor on over 60 scientific papers and patents.